Sriram S, Roberts C A
J Immunol. 1986 Jun 15;136(12):4464-9.
CR-EAE is an autoimmune T cell-mediated disease that can be induced in mice either by the injection of MSCH and CFA or by passive transfer of MBP-sensitized T cells. To evaluate the clinical relevance of anti-L3T4 antibodies in this relapsing, remitting disease, we studied the therapeutic benefits of such treatment on CR-EAE in animals when treatment was begun after the onset of initial paralytic signs. Animals treated biweekly with anti-L3T4 antibody had fewer relapses than control animals, and the histopathology of the brain and spinal cord showed fewer and less extensive lesions. Serial analysis of lymph node cell populations and antibody levels showed that animals treated with anti-L3T4 antibody had a depletion of the helper/inducer T cell population and did not develop a humoral response to the administered rat antibody. This study raises the possibility of treatment with antibodies against T cell subsets in established disease wherein this subset is known to play a crucial role.
慢性复发性实验性自身免疫性脑脊髓炎（CR-EAE）是一种自身免疫性T细胞介导的疾病，可通过向小鼠注射髓鞘碱性蛋白（MSCH）和完全弗氏佐剂（CFA）或通过被动转移髓鞘碱性蛋白（MBP）致敏的T细胞来诱导。为了评估抗L3T4抗体在这种复发缓解性疾病中的临床相关性，我们研究了在动物首次出现麻痹症状后开始治疗时，这种治疗对CR-EAE的治疗效果。每两周用抗L3T4抗体治疗的动物比对照动物复发次数更少，并且脑和脊髓的组织病理学显示病变更少且范围更小。对淋巴结细胞群体和抗体水平的系列分析表明，用抗L3T4抗体治疗的动物辅助/诱导性T细胞群体减少，并且对所给予的大鼠抗体未产生体液反应。这项研究提出了在已知该亚群起关键作用的已确诊疾病中用抗T细胞亚群抗体进行治疗的可能性。
